Biomedical Academic Entrepreneurship Through the SBIR Program

This paper considers the U.S. Small Business Innovation Research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy : early-stage financing and scientist involvement in commercialization. Using unique data on NIH supported biomedical researchers, we trace the incidence of biomedical entrepreneurship through SBIR and describe some of the characteristics of these individuals. To explore the importance of early-stage financing and scientist involvement, we complement our individual level data with information on scientist-linked and non-linked SBIR firms. Our results show that the SBIR program is being used as a commercialization channel by academic scientists. Moreover, we find that the firms associated with these scientists perform significantly better than other non-linked SBIR firms in terms of followon venture capital funding, SBIR program completion, and patenting. --Academic entrepreneurship,star scientists,SBIR,Venture Capital,innovation

Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR program

Do academic scientists bring valuable human capital to the companies they found or join? If so, what are the particular skills that compose their human capital and how are these skills related to firm performance? This paper examines these questions using a particular group of academic entrepreneurs – biomedical research scientists who choose to commercialize their knowledge through the U.S. Small Business Innovation Research Program. Our conceptual framework assumes the nature of an academic entrepreneurs? prior research reflects the development of their human capital. We highlight differences in firm performance that correlate with differences in the scientists? research orientations developed during their academic careers. We find that biomedical academic entrepreneurs with human capital oriented toward exploring scientific opportunities significantly improve their firms? performance of research tasks such as ?proof of concept? studies. Biomedical academic entrepreneurs with human capital oriented toward exploring commercial opportunities significantly improve their firms? performance of invention oriented tasks such as patenting. Consistent with prior evidence, there also appears to be a form of diminishing returns to scientifically oriented human capital in a commercialization environment. Holding the commercial orientation of the scientists? human capital constant, we find that increasing their human capital for identifying and exploring scientific opportunities significantly detracts from their firms? patenting performance. --Academic Entrepreneurship,SBIR Program,Human Capital,Biotechnology

Exploring the relationship between scientist human capital and firm performance: The case of biomedical academic entrepreneurs in the SBIR Program.

Do academic scientists bring valuable human capital to the companies they found or join? If so, what are the particular skills that compose their human capital and how are these skills related to firm performance? This paper examines these questions using a particular group of academic entrepreneurs - biomedical research scientists who choose to commercialize their knowledge through the U.S. Small Business Innovation Research Program. Our conceptual framework assumes the nature of an academic entrepreneurs' prior research reflects the development of their human capital. We highlight differences in firm performance that correlate with differences in the scientists' research orientations developed during their academic careers. We find that biomedical academic entrepreneurs with human capital oriented toward exploring scientific opportunities significantly improve their firms' performance of research tasks such as 'proof of concept' studies. Biomedical academic entrepreneurs with human capital oriented toward exploring commercial opportunities significantly improve their firms' performance of invention oriented tasks such as patenting. Consistent with prior evidence, there also appears to be a form of diminishing returns to scientifically oriented human capital in a commercialization environment. Holding the commercial orientation of the scientists' human capital constant, we find that increasing their human capital for identifying and exploring scientific opportunities significantly detracts from their firms' patenting performance.Academic entrepreneurship; Biotechnology; Human capital; SBIR program; Firm performance; Performance; Entrepreneurs; SBIR;

Biomedical Academic Entrepreneurship Through the SBIR Program

This paper considers the U.S. Small Business Innovation research (SBIR) program as a policy fostering academic entrepreneurship. We highlight two main characteristics of the program that make it attractive as an entrepreneurship policy: early-stage financing and scientist involvement in commercialization. Using unique data on NIH supported biomedical researchers, we trace the incidence of biomedical entrepreneurship through SBIR and describe some of the characteristics of these individuals. To explore the importance of early-stage financing and scientist involvement, we complement our individual level data with information on scientist-linked and non-linked SBIR firms. Our results show that the SBIR program is being used as a commercialization channel by academic scientists. Moreover, we find that the firms associated with these scientists perform significantly better than other non-linked SBIR firms in terms of follow-on venture capital funding, SBIR program completion, and patenting.

Nanotechnology Publications and Patents: A Review of Social Science Studies and Search Strategies

This paper provides a comprehensive review of more than 120 social science studies in nanoscience and technology, all of which analyze publication and patent data. We conduct a comparative analysis of bibliometric search strategies that these studies use to harvest publication and patent data related to nanoscience and technology. We implement these strategies on 2006 publication data and find that Mogoutov and Kahane (2007), with their evolutionary lexical query search strategy, extract the highest number of records from the Web of Science. The strategies of Glanzel et al. (2003), Noyons et al. (2003), Porter et al. (2008) and Mogoutov and Kahane (2007) produce very similar ranking tables of the top ten nanotechnology subject areas and the top ten most prolific countries and institutions.nanotechnology, research and development, productivity, publications, patents, bibliometric analysis, search strategy

Crossing borders; when science meets industry

Economic growth is ultimately driven by advances in productivity. In turn, productivity growth is driven by R&D and by utilisation of the public knowledge pool. This public knowledge pool is generated by universities and public research institutions. Underutilisation by firms of results from public research can deter economic growth, and the question then emerges how to bring science to the market. In this report we explore whether in Europe public knowledge is underutilised by firms, and investigate the quantitative importance of various knowledge transmission channels (such as publications, informal contacts, consulting). Next we study characteristics of universities and firms that may prevent an effective knowledge transfer. Finally we look at a number of policy initiatives designed to foster science-to-industry knowledge spillovers in the Netherlands and a selection of other countries.

Just how difficult can it be counting up R&D funding for emerging technologies (and is tech mining with proxy measures going to be any better?)

Decision makers considering policy or strategy related to the development of emerging technologies expect high quality data on the support for different technological options. A natural starting point would be R&D funding statistics. This paper explores the limitations of such aggregated data in relation to the substance and quantification of funding for emerging technologies. Using biotechnology as an illustrative case, we test the utility of a novel taxonomy to demonstrate the endemic weaknesses in the availability and quality of data from public and private sources. Using the same taxonomy, we consider the extent to which tech-mining presents an alternative, or potentially complementary, way to determine support for emerging technologies using proxy measures such as patents and scientific publications

From public labs to private firms: magnitude and channels of R&D spillovers

Introducing a new measure of scientific proximity between private firms and public research groups and exploiting a multi-billion euro financing program of academic clusters in France, we provide causal evidence of spillovers from academic research to private sector firms. Firms in the top quartile of exposure to the funding shock increase their R&D effort by 20% compared to the bottom quartile. We exploit reports produced by funded clusters, complemented by data on labor mobility and R&D public-private partnerships, to provide evidence on the channels for these spillovers. We show that spillovers are driven by outsourcing of R&D activities by the private to the public sectors and, to a lesser extent, by labor mobility from one to the other and by informal contacts. We discuss the policy implications of these findings

Creating a 21st Century national innovation system for a 21st Century Latvian economy

The Latvian economy made great strides in recovering from the economic shock of the early transition and the adverse aftereffects of the 1998 Russian financial crisis. Nevertheless, Latvia faces serious challenges to its future growth and prosperity despite these impressive achievements and the outward appearance of macroeconomic stability and economic progress. A wide variety of recent studies suggest that the Latvian economy is not particularly competitive and, even more worrisome, they indicate that Latvia is not well positioned to gain ground in the race for global competitiveness, prosperity, and rising standards of living. Most of Latvia's growth to date has come from one-off gains generated by structural reforms, privatization, and reallocating resources, not inexhaustible reservoirs of growth. Latvian enterprises will be able to sustain economic growth and create high wage jobs only by becoming internationally competitive, innovating, accumulating new knowledge and technology, and finding a high value added niche in the European and global division of labor. This paper is designed to help Latvian leaders develop a clear diagnosis of the innovation and competitiveness challenges facing Latvia as it prepares to enter the EU and, more important, design and implement policies and programs to ensure that Latvia reaps the maximum possible benefits from EU structural funds. Section II analyzes the current structure of Latvia's production, imports, and exports. Section III uses data from a number of competitiveness reports to benchmark Latvia's current progress against a number of comparator countries and to pinpoint Latvia's strengths and weaknesses as an innovative economy. Section IV offers a detailed list of potential policies and programs that could improve the competitiveness of Latvian enterprises and the efficiency of the Latvian National Innovation System. The recommendations include specific policies and programs to improve (1) the production of knowledge in Latvia, (2) the commercialization of technology produced by Latvian scientists, small companies, and research institutes, and (3) local firms'capacity to absorb, adapt, and adopt existing knowledge produced outside Latvia for use inside Latvia.ICT Policy and Strategies,Economic Theory&Research,Labor Policies,Environmental Economics&Policies,Agricultural Knowledge&Information Systems,Environmental Economics&Policies,Economic Theory&Research,Agricultural Knowledge&Information Systems,ICT Policy and Strategies,Banks&Banking Reform

Financing technology transfer

Global policy discussions increasingly focus on innovation and the knowledge economy as a driver of long-term growth. In parallel new forms of innovation processes are emerging, notably open innovation and innovation networks stressing the importance of connections between various stakeholders. Links between universities and the business sector are of particular importance as many inventions come out of universities but have to be further developed to become economically relevant innovations. New financing instruments and attracting private investors to technology transfer (TT) are necessary but difficult as the patterns of risk and information in this “in-between area” is complex: Technology is not basic anymore and it requires large amounts of capital to be scaled up – with uncertain market prospects. This paper addresses new financial instruments for TT, building on European Investment Fund’s experience in this field.Technology Transfer; Financing; Innovation; Commercialisation; Funding gap; Patents; Licensing; Intellectual Property